Viatris product management interviews test whether candidates understand how managing complex generics and off-patent pharmaceutical products differs from branded pharma or technology product management – where ANDA lifecycle management requires tracking patent expiration dates, paragraph IV certification challenges, and FDA review timelines in a competitive landscape where the first generic manufacturer to receive approval may earn 180-day market exclusivity that justifies accelerated commercial launch investment before the market opens to all generic competitors, where the portfolio rationalization imperative created by the Mylan-Upjohn combination requires evaluating which products across a portfolio spanning thousands of SKUs deserve continued investment versus discontinuation based on margin contribution, FDA compliance status, and market position, and where the 505(b)(2) NDA pathway for complex formulations like EpiPen creates a regulatory and IP strategy that differs from both the standard ANDA pathway for small-molecule generics and the NDA pathway for novel branded products. Product management at Viatris spans generic product ANDA lifecycle management (where product managers must track FDA review timelines, paragraph IV challenge litigation outcomes, and competitive ANDA approvals to determine the optimal commercial launch timing for generics entering markets where other manufacturers may have received earlier approval or 180-day exclusivity), complex generic and specialty product development management (where Dymista's azelastine/fluticasone combination and Yupelri's revefenacin nebulized LAMA represent products with complex formulation, device, or clinical characterization requirements that demand regulatory strategy, clinical development management, and IP protection work beyond standard generic product management), portfolio rationalization and SKU optimization (where the combination of Mylan's and Upjohn's product portfolios created overlapping product lines, sub-scale market positions, and non-strategic SKUs that require systematic evaluation against commercial viability and manufacturing complexity criteria to identify discontinuation candidates), and international market product strategy (where Viatris's branded generic portfolio in emerging markets requires country-by-country pricing, regulatory registration, and competitive positioning management that differs from the US formulary-access-driven model).
Start your free Viatris Product Management practice session.
What interviewers actually evaluate
ANDA Lifecycle Strategy, Complex Generic Development, and Portfolio Rationalization
Viatris product management interviews probe whether candidates understand how pharmaceutical product management differs from technology or consumer product management in the regulatory pathway determinism (the commercialization timeline, competitive entry sequence, and market exclusivity period for a generic product are determined by FDA approval timing and patent litigation outcomes rather than by product development quality alone – where a product manager who does not track the ANDA competitive landscape including other manufacturers' estimated approval dates and first-to-file exclusivity status cannot accurately forecast the commercial window in which Viatris's product will face limited versus full generic competition), the gross-to-net pricing constraint on product economics (pharmaceutical product economics must account for the mandatory and voluntary price adjustments that reduce WAC to net revenue – where a product manager evaluating a new product launch must model not just the WAC price point and volume assumptions but the PBM rebate levels required for formulary access, Medicaid best price obligations created by commercial discounts, and 340B ceiling price limitations at covered entity purchasers that determine the true revenue per unit the business will receive), and the patent strategy intersection (generic product launches that involve paragraph IV certifications – challenging an innovator's patent as invalid or non-infringed before patent expiration – create litigation risk and potential 30-month stay of FDA approval that product managers must model into launch timing assumptions, while the possibility of an at-risk launch before patent litigation is resolved creates a product investment decision that depends on legal assessment of the probability and timing of adverse patent rulings).
The biosimilar business divestiture to Biocon Biologics completed in November 2022 is a critical portfolio decision context for Viatris product management interviews: the decision to divest a growing biosimilar business reflects a strategic assessment that Viatris's competitive advantages and capital allocation priorities do not support the clinical development investment, regulatory pathway complexity, and commercial infrastructure required for biosimilar success – a judgment that product managers in other functions must understand and be able to articulate when explaining Viatris's current product strategy.
What gets scored in every session
Specific, sentence-level feedback.
| Dimension | What it measures | How to answer |
|---|---|---|
| Generic ANDA competitive landscape analysis and launch timing strategy | Do you understand how to develop Viatris's launch timing strategy for a generic product where multiple ANDAs have been filed by competing manufacturers – how to assess which competitors are likely to receive FDA approval before Viatris based on their filing date, the complexity of their ANDA review, and whether any manufacturer holds a first-to-file position that may trigger 180-day exclusivity, what the commercial investment decision looks like for an at-risk launch before paragraph IV patent litigation is resolved when the upside of early market entry must be weighed against the potential liability of launch if the patent is found valid and infringed, and how to structure the commercial launch plan for a product entering a market where multiple generic manufacturers have already been approved and price competition has already compressed the market to commodity margins? We flag product answers that treat generic product launch as a single-event decision without engaging with the competitive ANDA landscape, patent litigation timeline, and exclusivity period economics that determine whether a generic launch creates meaningful commercial value. | Competitive ANDA approval timeline assessment, at-risk launch decision framework, exclusivity period commercial strategy |
| Complex generic product development and 505(b)(2) regulatory strategy | Can you describe how to manage the product development and regulatory strategy for a complex generic product – how the 505(b)(2) NDA pathway differs from the standard ANDA pathway in terms of clinical study requirements, FDA review standards, and market exclusivity opportunities, what the clinical endpoints that demonstrate therapeutic equivalence for a complex formulation or device-drug combination product include beyond standard bioequivalence studies, and how to develop the IP strategy that protects a complex generic product's commercial position after approval against follow-on generic competitors who may attempt to file ANDAs or abbreviated 505(b)(2) applications? We score whether your complex product development approach engages with the FDA pathway selection decision and clinical characterization requirements that distinguish complex generic development from standard bioequivalence-based ANDA development. | 505(b)(2) versus ANDA pathway selection, complex product clinical characterization, IP protection strategy |
| Portfolio rationalization and product discontinuation decision framework | Do you understand how to lead Viatris's ongoing portfolio rationalization effort – how to develop the evaluation framework that systematically assesses each product's contribution margin, FDA compliance status, manufacturing complexity, and strategic fit, what the discontinuation decision process requires including FDA notification and patient impact assessment for products with limited therapeutic alternatives, and how to sequence discontinuation decisions to maximize the manufacturing capacity and commercial team bandwidth that is freed for higher-priority products without creating supply gaps that harm patients dependent on the discontinued products? We detect product answers that treat portfolio rationalization as a simple margin ranking exercise without engaging with the FDA notification requirements for discontinuation and the patient access implications for products without readily available alternatives. | Contribution margin and strategic fit evaluation framework, FDA drug discontinuation notification, patient access impact assessment |
| International market product strategy for branded generic portfolio | Can you describe how to develop Viatris's product strategy for the former Upjohn branded generic portfolio in emerging markets – how country-by-country pricing decisions must balance local market affordability with the global reference pricing implications when a low price in one market affects the net price floor in markets that use international reference pricing, what the regulatory registration maintenance strategy looks like for products with dozens of country-level marketing authorization dossiers that require periodic renewal and variation filings, and how to prioritize commercial investment across emerging markets where branded generic products hold different competitive positions and growth trajectories? We flag product answers that treat international branded generic strategy as a simple geographic expansion exercise without engaging with the reference pricing cascade risk and country-level registration maintenance complexity that multi-market portfolio management requires. | Reference pricing cascade risk management, marketing authorization maintenance prioritization, emerging market commercial investment allocation |
How a session works
Step 1: Choose a Viatris product management scenario – generic ANDA competitive landscape and launch timing strategy, complex generic product development and 505(b)(2) regulatory pathway, portfolio rationalization and product discontinuation decision framework, or international branded generic market strategy.
Step 2: The AI interviewer asks realistic Viatris-style questions: how you would develop the launch strategy for Viatris's generic version of a branded sleep medication whose primary patent expired six months ago and where FDA has approved three other generic manufacturers, with a fourth applicant who filed first and may have been entitled to 180-day exclusivity but whose exclusivity period may have been forfeited due to commercial marketing failure – including how you would assess whether the 180-day exclusivity period is still active or has been forfeited, what the competitive price point analysis looks like for a market where three approved generics are already competing, and how to structure the commercial launch investment decision when the market may already be near commodity pricing; how you would evaluate the portfolio rationalization decision for 15 low-volume Viatris generic products that each generate less than $2 million in annual net revenue but collectively represent a significant burden on quality and manufacturing operations – including what the evaluation framework is for each product's margin contribution, manufacturing resource consumption, FDA compliance compliance footprint, and patient access implications, how to sequence the discontinuation notifications to FDA's drug shortage system required for products with limited market availability, and how to communicate the portfolio pruning decisions to Viatris's distribution partners who manage the affected products in their ordering systems; or how you would develop the pricing strategy for a new Dymista indication that Viatris is pursuing through a supplemental NDA filing – weighing the additional clinical development cost against the revenue opportunity from a new patient population and the WAC adjustment options within the gross-to-net constraints that payer market access requires.
Step 3: You respond as you would in the actual interview. The system scores your answer on ANDA lifecycle strategy, complex product development, portfolio rationalization, and international market strategy.
Step 4: You get sentence-level feedback on what demonstrated genuine pharmaceutical product management expertise and what needs stronger ANDA competitive analysis or portfolio rationalization framework specificity.
Frequently Asked Questions
What is an ANDA and what is the 180-day exclusivity period?
An Abbreviated New Drug Application is the FDA regulatory pathway for generic drug approval, where the applicant demonstrates that their generic product is bioequivalent to the reference branded product and meets the same quality standards, without requiring new clinical efficacy trials. When a generic applicant files an ANDA that includes a Paragraph IV certification challenging one or more of the branded product's listed patents as invalid or non-infringed, the first generic manufacturer to file with a Paragraph IV certification is eligible for a 180-day period of marketing exclusivity during which FDA cannot approve other generic manufacturers' ANDAs – creating a significant commercial advantage for the first-to-file applicant if the patent challenge is ultimately successful or settled favorably. The 180-day exclusivity period is a major driver of generic product competitive strategy because the product manager who successfully achieves first-to-file position and wins the patent challenge can command higher prices during the exclusivity window before the market becomes fully competitive.
What is the 505(b)(2) NDA pathway and when does Viatris use it?
Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act allows NDA applicants to rely partly on published literature or FDA's prior findings of safety and efficacy for a reference product when seeking approval for a product that is not identical to the reference product but that is related. Unlike an ANDA that requires bioequivalence to a specific reference listed drug, a 505(b)(2) application can support approval of a product with a different formulation, route of administration, dosage form, or dosage strength that provides a clinical advantage over the reference product. Viatris uses the 505(b)(2) pathway for products like Dymista that combine established active ingredients in novel formulations, allowing the company to obtain NDA approval (with potential patent protection for the new formulation) rather than ANDA approval for what would be classified as a generic.
Why did Viatris divest its biosimilar business to Biocon Biologics?
Viatris completed the divestiture of its biosimilar business to Biocon Biologics in November 2022, transferring the commercial and development biosimilar portfolio to Biocon in exchange for approximately $3.3 billion including an equity stake in Biocon Biologics. The divestiture reflected a strategic assessment that Viatris's portfolio rationalization priorities, capital allocation constraints from post-merger debt, and competitive position in the biosimilar market made maintaining and growing a biosimilar business suboptimal relative to focusing capital on complex generics and branded off-patent products where Viatris's manufacturing capabilities and commercial relationships provided more durable competitive advantages. For Viatris product management, the divestiture means that biosimilar development competencies and commercial responsibilities now reside with Biocon, and Viatris's product portfolio focus is complex generics, branded generics in emerging markets, and off-patent branded products in the US market.
How does Viatris approach portfolio rationalization across thousands of SKUs?
The combination of Mylan's and Upjohn's product portfolios created a Viatris product portfolio spanning thousands of individual SKUs across dosage forms, strengths, and markets – many of which require ongoing FDA registration maintenance, manufacturing capacity allocation, quality system oversight, and commercial support. Viatris's portfolio rationalization effort systematically evaluates each product against criteria including annual net revenue contribution, manufacturing complexity and cost, FDA compliance status and remediation burden, availability of alternative products for patients, and strategic fit with Viatris's core market positions. Products that fall below commercial viability thresholds and that have readily available therapeutic alternatives are candidates for controlled discontinuation, requiring advance notice to FDA's drug shortage surveillance system under FDCA Section 506C when the product has limited market availability.
How does international reference pricing affect Viatris's global pricing strategy?
Many countries use international reference pricing (IRP) systems that establish their national reimbursement price for a drug based on the prices the same drug is sold at in reference countries. When Viatris sets a price in one country – for example, accepting a low net price in a government tender for an emerging market country – that low price can trigger mandatory price reductions in other countries that reference the first country's price in their IRP calculations. Product managers responsible for international pricing must maintain a price sensitivity model that forecasts the cascade effect of pricing decisions in individual markets across the reference pricing network, and must coordinate with country-level commercial teams to sequence pricing decisions in ways that minimize adverse reference pricing impacts in higher-value markets that are commercially more significant.
Also practice
One full session free. No account required. Real, specific feedback.
